Tarsus Pharmaceuticals, Inc.TARSNASDAQ
Loading
SG&A Expense Growth Recovery in ProgressRecovering
Percentile Rank48
3Y CAGR-5.7%
5Y CAGR-24.2%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-5.7%/yr
Quarterly compound
5Y CAGR
-24.2%/yr
Recent acceleration
Percentile
P48
Within normal range
vs 5Y Ago
0.3x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 20.30% |
| Q3 2025 | 5.46% |
| Q2 2025 | 21.20% |
| Q1 2025 | 23.13% |
| Q4 2024 | 19.20% |
| Q3 2024 | -1.50% |
| Q2 2024 | 13.99% |
| Q1 2024 | 19.93% |
| Q4 2023 | 41.82% |
| Q3 2023 | 51.93% |
| Q2 2023 | 34.49% |
| Q1 2023 | 1.42% |
| Q4 2022 | 24.19% |
| Q3 2022 | 13.56% |
| Q2 2022 | 30.58% |
| Q1 2022 | 17.34% |
| Q4 2021 | 1.51% |
| Q3 2021 | -1.81% |
| Q2 2021 | 31.67% |
| Q1 2021 | 32.65% |
| Q4 2020 | 80.93% |
| Q3 2020 | 40.89% |
| Q2 2020 | 151.82% |
| Q1 2020 | 56.59% |
| Q4 2019 | 80.84% |
| Q3 2019 | 0.00% |
| Q2 2018 | 0.00% |
| Q1 2018 | 0.00% |